Abstract
Cancers harbor many somatic mutations and germline variants. We hypothesized that the combined effect of germline variants that alter the structure, expression, or function of protein-coding regions of cancer-biology related genes (gHFI) determines which and how many somatic mutations (sM) must occur for malignant transformation. We show that gHFI and sM affect overlapping genes and the average number of gHFI in cancer hallmark genes is higher in patients who develop cancer at a younger age (r = -0.77, P = 0.0051), while the average number of sM increases in increasing age groups (r = 0.92, P = 0.000073). A strong negative correlation exists between average gHFI and average sM burden in increasing age groups (r = -0.70, P = 0.017). In early-onset cancers, the larger gHFI burden in cancer genes suggests a greater contribution of germline alterations to the transformation process while late-onset cancers are more driven by somatic mutations.
Introduction
Cancer is traditionally viewed as a disease of accumulated genomic "hits." While research has historically prioritized somatic mutations (sM)—genetic errors acquired through aging and environmental exposure—the role of the cumulative inherited genetic burden remains less understood. Beyond well-known high-penetrance mutations like BRCA1, this study investigates how the total burden of germline High-Functional Impact (gHFI) variants influences the threshold for malignant transformation. The authors propose a "see-saw" model: a high inherited burden in cancer-relevant pathways provides a "head start," requiring fewer subsequent somatic mutations to trigger the disease.
Methodology
The researchers developed the gHFI metric to identify inherited changes predicted to alter protein structure or function using tools like MetaSVM and the ClinVar database. The analysis focused on 1,558 manually curated cancer hallmark genes across 21 critical biological pathways, such as DNA repair and cell cycle control.
To validate these findings, the study utilized three independent genomic datasets:
- The Cancer Genome Atlas (TCGA): 7,468 cases (primary discovery cohort).
- Pan-Cancer Analysis of Whole Genomes (PCAWG): 1,487 cases.
- UK Biobank (UKBB): 7,198 cases.
Patients were categorized into five-year age intervals, and correlations between age at diagnosis, gHFI burden, and sM burden were analyzed using Pearson correlation and linear regression, controlling for cancer type and European ancestry.
Results and Key Insights
The study identified a distinct distribution of functional variants across the TCGA cohort. While somatic mutations typically outnumber germline variants on a per-case basis, the cumulative impact of the latter is significant in early-onset cases.
The Inverse Correlation of Burden
A central finding is the strong negative correlation ($r = -0.77, P = 0.0051$) between age at diagnosis and the number of gHFI variants in hallmark genes. Conversely, somatic mutation burden shows a strong positive correlation with age ($r = 0.92, P = 0.000073$). This suggests that if a patient's "germline bucket" is relatively full at birth, their "somatic bucket" requires less accumulation to reach the threshold of malignancy ($r = -0.70, P = 0.017$ for the inverse link between gHFI and sM).
Pathway and Gene Overlap
Germline and somatic hits do not occur in isolation; they target the same hallmark pathways. Analysis at the gene level revealed a substantial overlap, with 1,253 genes being affected by both somatic and germline functional variants across the study population.
Discussion
The findings suggest that late-onset cancers are primarily driven by the slow, age-related accumulation of somatic errors. In contrast, early-onset cancers are heavily influenced by the genetic hand dealt at birth. Notably, only 0.38% of the identified gHFI variants were previously listed as pathogenic in ClinVar, indicating that cancer risk often stems from a cumulative burden of variants that are individually considered of low clinical significance.
Future research is required to determine if these patterns hold across non-European populations and to account for variants in non-coding regulatory regions, which were not included in this exome-focused analysis.
Summary updated